Showing 4181-4190 of 8897 results for "".
- New JAMA Dermatology Publication Features AID Accelerator Fund to Enable Progress of Promising Early-stage Scientific Technologieshttps://practicaldermatology.com/news/new-jama-dermatology-publication-features-aid-accelerator-fund-to-enable-progress-of-promisingearly-stage-scientific-technologies/2457810/A new article, "Catalyzing Future Drug, Device, and Information Technology Breakthroughs in Dermatology", in JAMA Dermatology features the Advancing Innovation in Dermatology (AID) Accelerator Fund. AID has created this mechanism to help enable and speed the product development
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in For
- DefenAge® Skincare Trio Performs Well in New Studyhttps://practicaldermatology.com/news/defenage-skincare-trio-performs-well-in-new-study/2457818/Progenitor Biologics’ DefenAge® Skincare, a-three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” according to new research in the
- With New Team, Revance Readies for Launch of their Botox Competitorhttps://practicaldermatology.com/news/with-new-team-revance-readies-for-launch-of-their-botox-competitor/2457819/With the advent of four new positions, Revance Therapeutics is expanding their commercialization team in anticipation of the product launch of for DaxibotulinumtoxinA for Injection (RT002) in the treatment of glabellar lines.
- American Academy of Dermatology Elects New Officers, Board Membershttps://practicaldermatology.com/news/american-academy-of-dermatology-elects-new-officers-board-members/2457825/The American Academy of Dermatology named its new officers and board members who will represent the more than 19,000 physicians who specialize in the diagnosis and medical, surgical and cosmetic treatment of skin, hair, and nail conditions. These officers and board members, all of whom are board-
- Did New USPSTF Recommendations on Skin Cancer Prevention Counseling Go Far Enough? AADA Reactshttps://practicaldermatology.com/news/did-new-uspstf-recommendations-on-skin-cancer-prevention-counselling-go-far-enough-aada-reacts/2457830/The U.S. Preventive Services Task Force (USPSTF) is calling for behavioral counseling to help reduce the risk of skin cancer from ultraviolet (UV) radiation in people aged 6 months to 24 years with fair skin types. The new USPSTF recommendation statement updates a 2012 recommendation on b
- Newborn Skin May Pave the Way Toward New Eczema Lotionhttps://practicaldermatology.com/news/newborn-skin-may-pave-the-way-for-new-eczema-lotion/2457844/Newborns emerge from the womb covered with a waxy substance called the vernix, which protects their skin from drying, and researchers have begun to realize that the vernix also helps babies adapt to life outside the womb by stimulating cells in the skin to make water-resistant lipid molecules.
- New Recommendations Aim to Minimize Biotin Interference in Clinical Immunoassayshttps://practicaldermatology.com/news/new-recommendations-aim-to-minimize-biotin-interference-in-clinical-immunoassays/2457842/As the popularity of biotin has grown, so has the incidence of this vitamin interfering with critical medical tests, and now a review in The Journal of Applied Laboratory Medicine provides expert recommendat
- Sensus Healthcare Launches New Line of Laser Systems for Clinical and Aesthetic Dermatologyhttps://practicaldermatology.com/news/sensus-healthcare-launches-new-line-of-laser-systems-for-clinical-and-aesthetic-dermatology/2457846/Sensus Healthcare, Inc. has launched Sensus Laser Systems, a unique multi-platform line of high-quality, cost-effective dermatological lasers to complement its existing superficial radiation therapy (SRT) system, which is used for non-invasive treatment of non-melanoma skin cancers and keloids. T
- Novartis' Xolair Recommended in New Global Chronic Urticaria Guidelinehttps://practicaldermatology.com/news/novartis-xolair-recommended-in-new-global-chronic-urticaria-guideline/2457849/A new global guideline on chronic urticaria (CU) recommends Xolair (omalizumab), indicated as add-on therapy for the treatment of chronic spontaneous urticaria (CSU), for patients who are not responding to antihistamines. Xolair is the only licensed treatment option for CSU, a type of CU, for pat